@adamfeuerstein adamfeuerstein

Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY. · Analyst brief as of 2026-06-22.

Adam Feuerstein disclosed no positions or directional trades; the window is mainly biotech news and scrutiny. He was constructive on QURE’s FDA reversal and skeptical of NWBO and IBRX, while pushing back on reflexive biotech sale pressure around RVMD and APGE-style M&A speculation. No explicit late-week flip or add/trim signal appears in the payload.

The author’s attention is concentrated on biotech regulatory catalysts and evidence quality, with QURE as the clear positive cluster and NWBO/IBRX as negative scrutiny targets. There are no CALL_DIRECTIONAL or POSITION_DISCLOSURE signals, so no explicit adds, trims, exits, or confirmed flip can be identified. Concentration risk is highest in the QURE theme because every signal there is single-name regulatory coverage.

Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.